ERBB2 and pancreatic neoplasm: We found that the combination of cetuximab (anti-EGFR mAb) and trastuzumab (anti-HER2 mAb) is efficient against pancreatic cancer (10–12), a disease with unmet medical needs and poor prognosis (15).